In T2D, sitagliptin administration has been associated with decreased expression of CD26 in mononuclear cells [41] and conversely, in T2D patients not on DPPIV inhibitor treatment, CD26 expression was higher in CD4+ and CD8+ T cells, although its expression was influenced by glycaemia [42]. Here, CD4 is linked to type 2 diabetes mellitus.